3 studies on Albiglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently curates 3 dated studies on Albiglutide. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.
Dulaglutide reduced stroke risk by 23% (RR: 0.77) and semaglutide lowered cardiovascular mortality by 26% (RR: 0.74) in T2DM patients, a network meta-analysis of 67,769 found.
Understanding the sex-based heterogeneity in drug response is crucial for optimizing personalized medicine approaches in CKMH. If significant differences are found, it could lead to sex-specific prescribing guidelines…
Free, no account — handy when you're working with Albiglutide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account